Allison White, MD
Nephrology · Greenwood, MSNPI 1760559751
Payments from drug & device makers
What this record shows
This record is dominated by other: $3,328 of the $4,346 with a category attached, or 76.6%. International Rehabilitative Sciences, Inc accounts for 76.6% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $3,604, more than ten times the $38 reported in 2019.
Across 44 payments — averaging $98.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- International Rehabilitative Sciences, Inc$3K
- Fresenius USA Marketing, Inc.$412
- Novartis$152
- AstraZeneca$140
- Akebia Therapeutics Inc$72
- Baxter Healthcare$61
- plus $179 from 7 others
What the payments were for
- Food & beverage$1,00523%
- Education$120%
- Other$3,32877%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| International Rehabilitative Sciences, Inc | 1 | $3,328 |
| Fresenius USA Marketing, Inc. | 23 | $412 |
| Novartis | 4 | $152 |
| AstraZeneca | 2 | $140 |
| Akebia Therapeutics Inc | 4 | $72 |
| Baxter Healthcare | 1 | $61 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Amgen | 2 | $34 |
| Travere Therapeutics, Inc. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| GSK | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Ardelyx, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,346 in reported general payments places this provider in the 80th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 240 | $512,411 |
| AuryxiaFerric Citrate | 37 | $67,874 |
| Sevelamer Carbonate | 433 | $49,581 |
| XphozahTenapanor Hcl | 11 | $49,064 |
| RenvelaSevelamer Carbonate | 36 | $41,870 |
| FarxigaDapagliflozin Propanediol | 14 | $12,479 |
| Lanthanum Carbonate | 20 | $7,451 |
| Calcium Acetate | 24 | $1,530 |
| Potassium Chloride | 52 | $512 |
| Furosemide | 83 | $437 |
| Minoxidil | 27 | $395 |
| Fluconazole | 18 | $292 |
| Lactulose | 17 | $279 |
| Metoprolol Tartrate | 31 | $135 |
| Amlodipine Besylate | 31 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $412 | $512,411240 claims |
| Akebia Therapeutics IncAuryxia | $72 | $67,87437 claims |
| AstraZenecaFarxiga | $140 | $12,47914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 105 nephrology providers in Mississippi.
Other nephrology in Greenwood
- Mohit AhujaFlowood$427K
- Padam HirachanNatchez$29K
- Brian RifkinHattiesburg$23K
- Otis GowdyMeridian$12K
- Richard MillerBrookhaven$10K
- Thomas WooldridgeTupelo$8K
- Steven WagnerFlowood$6K
- John Martin LeeTupelo$6K
- Francis PhillippiFlowood$6K
- Son LamOxford$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.